Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia

被引：0
|
作者：
Burnett, John R. [1 ]
机构：
[1] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, PathW Lab Med WA, Perth, WA 6847, Australia
来源：
CURRENT OPINION IN MOLECULAR THERAPEUTICS | 2006年 / 8卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
ISIS-301012 is an antisense oligonucleotide inhibitor of apolipoprotein B-100, which is being developed by Isis Pharmaceuticals Inc for the potential treatment of hypercholesterolemia. A subcutaneous injectable formulation is currently undergoing phase II clinical trials, while phase I trials are underway with an oral formulation of the drug.
引用
收藏
页码：461 / 467
页数：7
相关论文
共 50 条
12345